Patent: 10,046,000
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 10,046,000
| Title: | Use of 2-methylene-19-nor-(20S)-1.alpha.,25-Dihydroxyvitamin D.sub.3 to treat and prevent secondary hyperparathyroidism in a subject having renal failure |
| Abstract: | Disclosed are methods of administering 2-methylene-19-nor-(20S)-1.alpha.,25-dihydroxyvitamin D.sub.3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism. |
| Inventor(s): | DeLuca; Hector F. (Deerfield, WI), Plum; Lori A. (Arena, WI), Zella; Julia B. (Horicon, WI), Clagett-Dame; Margaret (Deerfield, WI) |
| Assignee: | Wisconsin Alumni Research Foundation (Madison, WI) |
| Application Number: | 15/604,069 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,046,000 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,046,000
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Nps Pharmaceuticals, Inc. | NATPARA | parathyroid hormone | For Injection | 125511 | 01/23/2015 | See Plans and Pricing | 2032-06-29 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
